Pieris Pharmaceuticals, Inc.
https://www.pieris.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pieris Pharmaceuticals, Inc.
Deal Watch: BI Acquires Nerio For Novel Immune Checkpoint Inhibitor
Featuring deals involving Novartis/Dren, Palvella/Pieris, Eyenovia/Senju, Addex/Johnson & Johnson, Agilent/BioVectra, Meitheal/Nabriva, plus tech transfer agreements and deals in brief.
Finance Watch: FibroGen, Amarin And Others Downsize To Survive
Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.
Pieris Looks For Way Out After AstraZeneca Exits Respiratory Collaboration
The US biotech is hoping to either partner off its wholly owned pipeline or become a target for an acquisition or merger after AstraZeneca’s asthma exit left it with dwindling cash, and a need to cut costs.
FibroGen Rocked By Second Pivotal Pamrevlumab Failure – This Time In IPF
Months after a disappointment in Duchenne muscular dystrophy, the US firm’s pamrevlumab has missed the mark in a pivotal idiopathic pulmonary fibrosis trial, boding poorly for other trials and forcing the firm to enter cost-cutting mode.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Marika Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice